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Brief Communication
PREVALENCE OF ANTIBIOTIC RESISTANCE AMONG
BACTERIA ISOLATES OF LOWER RESPIRATORY TRACT
INFECTION IN COPD SHAHREKORD – IRAN, 2005
Reza Imani1, Hamid Rouhi2, Forouzan Ganji3
ABSTRACT
Background: Bacterial infection is one of the several important causes of exacerbations of chronic
obstructive pulmonary disease (COPD). Antibiotic resistance has increased in all the major
pathogens. The objective of this study was investigate frequency of drug resistance of species
from LRTs.
Methods: This cross sectional study was performed in Hajar hospital of shahrekord–Iran.
Protected brush samples were obtained from the lower respiratory tract by bronchoscopy in
both hospitalized and ambulatory 54 COPD patients with exacerbations yield. The in vitro
susceptibilities of the isolates to 6 antimicrobial agents were then determined by the broth
microdilution test.
Results: Among the s. pneumonia isolates tested 5.9% and 94.1% were intermediate and high
level resistant to penicillin and ampicillin respectively. 58.8% of isolates were erythromycin
resistance. H.influenzae isolates were 100% resistance to penicillin and ampicillin.
Conclusion: Antibiotics are an important part of the treatment of COPD, suggesting that every
effort should be made to conserve sensitivity of antibiotic by using them appropriately.
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INTRODUCTION
Chronic obstructive pulmonary disease
(COPD) is a chronic, smoking – related inflam-
matory disorder of the lungs.1-3 Patients with
chronic bronchitis are more susceptible to
infections. Mucus hypersecretion, which is the
hallmark of chronic bronchitis, is particularly
associated with mortality from an infectious
cause.4
There is general agreement that the bacterial
species most commonly isolated from sputum
and lower respiratory tract during acute
exacerbations of COPD are nontypable
H.influenzae, streptococcus pneumoniae and
Moraxella catarrhalis.5,6 In recent years, there
has been a dramatic rise in antibiotic resistance
among common respiratory pathogens. For
example before 1987, <1% of pneumococci in
the USA demonstrated high–level resistance to
penicillin.7 In 1997 overall penicillin resistance
had reached to 43.8%.8
Patients with chronic obstructive pulmonary
disease are generally subjected to multiple regi-
mens of antimicrobial treatment. It is difficult
to decide whether patient characteristics or the
risk of antibiotic resistance should influence
choice of empiric antibiotic treatment. This
study was performed to investigate the
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frequency of drug–resistant bacterial species
commonly isolated from lower respiratory tract
by bronchoscopy.
MATERIALS AND METHODS
This cross sectional study was performed in
Hajar hospital of Shahrekord - Iran in 2005.
Protected brush samples were obtained from
the lower respiratory tract by bronchoscopy in
both hospitalized and ambulatory 54 patients
with exacerbations yield. The pathogens
collected for study were streptococcus pneu-
monia, Haemophilus influenzae, Moraxella
catarrhalis.
In vitro susceptibility testing was performed
by the broth micro dilution test according to
guidelines of the National committee for clini-
cal laboratory standards (NCCLS).9 The MICs
of six antimicrobial drugs, penicillin, ampicil-
lin, erythromycin, ciprofloxacin, ceftriaxone,
ofloxacin were determined by a standardized
microdilution method in 0.1ml volumes of Cat-
ion – adjusted Muller – Hinton broth with 5%
lysed horse blood . The microdilution plate was
inoculated with a disposable inoculator so that
the final inoculum was 5 * 10cfu/ml, and was
incubated at 37 c for 20 hr.10 To analyze the
factors such as age and sex for acquiring
bacterial pneumonia was obtained at the time
of patient enrollment in the study. Chi square
and independent t test were performed to
evaluate that factors.
RESULTS
Our result showed that culture was positive
for 23 (40%) isolates. There were no significant
difference between results of culture in vari-
able of age and sex (P>0.05). Table-I
DISCUSSION
In this study we used bronchoscopy
techniques to avoid nasopharyngeal contami-
nation of expectorated sputum. Data from this
study revealed 60% were negative for bacte-
rial culture. We presume that main cause of
these infections were viral agents and atypical
pathogen. Our data from this study revealed
high frequency of pneumococcal penicillin and
ampicillin resistance. In 1998 The ANSORP
study reported penicillin resistance in Korea
almost 80% of all isolates. Pneumococcal drug
resistance in Nagasaki, Japan, was also as se-
rious as in Korea.11 In France, the prevalence
of penicillin – resistant s. pneumoniae was
53.3% of submitted isolates in 1992. At the same
time Germany had low resistance (7.2%).12
According to the data from the present study
the prevalence rate of erythromycin among
s.pneumonia was 75% isolates and about
ciprofloxacin 29.4% isolates. Reported rates of
erythromycin resistance in the western Hemi-
sphere were high in France (58.1%) Spain
(57.1%) and the eastern south-central parts of
the United States (47%) Reports from Hong
Kong and Taiwan showed that 80 to 91% of
pneumococcal Isolates were resistant to
erythromycin.13,14
This study revealed penicillin, ampicillin
resistance 100% for H.influenzae and
M.catarrhalis.
In two studies beta-lactamase production
was found in 33.4% of H.influenzae and 95%
of M.  catarrhalis.15,16 In Hong Kong investiga-
tors demonstrated the high rates of resistance
of s.pneumoniae isolates to various
fluoroquinolones.14 Recently attention has also
been drawn to decreased susceptibility of S.P
to fluoroquinolones, perhaps reflecting in-
creased use of this class of antibiotic. Use of
antibiotics in anima husbandry and agriculture
is contributing to the problem. Risk factors for
multi drug resistant S.pneumoniae includes
prior antibiotic use, extremes of age and
hospitalization. High rates (>15%) of
B-lactamase production were found in the UK,
Antibiotic resistance in LRTI in COPD
Table-I: Distribution of antibiotic resistance among bacteria isolates of LRTIs
Pathogens No. of   Penicillin   Ampicillin Erythromycin Ciprofloxacin  Ceftriaxone   Ofloxacin
isolates Inter Resist Inter Resist Inter Resist Inter Resist Inter Resist Inter Resist
S.Pneumonia 17 5.9 94.1 5.9 94.1 35.3 58.8 17.6 11.8 11.8 5.9 23.5 11.8
H.influenzae 4 0.0 100 0.0 100 50 25 75 25 75 25 75 25
M.catarrhalis 2 0.0 100 100 0.0 100 0.0 0.0 0.0 0.0 0.0 0.0 0.0
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France, Belgium and Spain.12,16 92.2% of 371
isolates of M. catarrhalis collected in Europe
in 1998 produced B- lactamase.12
According to our data the prevalence of
erythromycin–resistant H. influenzae is 50% of
isolates where as isolates from France showed
the same result.12 Resistance to the Erythromy-
cin is associated with penicillin resistance.17
Our data showed no fluoroquinolones
resistance for isolates of M.catarrhalis.
Fluoroquinolone resistance was detected in
UK, France and Spain.12,18 Differences in the
prevalence of antimicrobial resistance in coun-
tries may be due to several factors. Different
patterns of antimicrobial usage, which lead to
variable selective pressure on resistance, might
be one of the primary factors.19 Other factors
could be the distribution of specific serotypes
and the spread of resistant clones within cer-
tain regions. Respiratory tract infections are the
most common indication for antibiotic pre-
scription, accounting for 60% of all scripts in
the UK. In Europe, >80% of all LRTI are treated
with antibiotics.19 Healthcare systems around
the world are attempting to minimize costs and
at the same time improve overall quality of
care. As such continuous study for drug resis-
tance and providing guidelines for the use of
antibiotics is suggested.
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